UPDATE: SVB Leerink On BridgeBio Price Target Raise: Firm Notes Additional Phase 2 Data Of Encaleret Shows Treatment 'Continues To Be Well-Tolerated With No Serious Adverse Events'; Sees Co. Plans To Meet With FDA By YE21 With Phase 3 Initiation In FY22